Aclaris Therapeutics Initiates IND-Directed Program for A-101 for the Treatment of Seborrheic Keratosis, Common Type of Skin Tumor  
11/6/2013 10:15:43 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

MALVERN, Pa.--(BUSINESS WIRE)--Aclaris Therapeutics Inc., a privately-held specialty pharmaceutical company dedicated to developing dermatological therapeutics, announced today the initiation of the first clinical trial of the company’s lead product A-101, a topically-applied therapy. A-101 is being investigated in adult patients for the removal of seborrheic keratosis, one of the most common types of benign skin tumors.

Help employers find you! Check out all the jobs and post your resume.